Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 6/20 | 0.44 |
| ▸ | CTSL | P07711 | 4/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16143229 | 0.90 | CTSB (0.44) | CTSBCTSLCTSKABCG2 | |
| SCHEMBL13091688 | 0.90 | CTSB (0.44) | CTSBCTSLCTSKABCG2 | |
| SCHEMBL463921 | 0.90 | CTSB (0.44) | CTSBCTSLCTSKABCG2 | |
| SCHEMBL464081 | 0.90 | CTSB (0.44) | CTSBCTSLCTSKABCG2 | |
| SCHEMBL12012606 | 0.90 | CTSB (0.44) | CTSBCTSLCTSKABCG2 | |
| SCHEMBL464041 | 0.89 | CTSK (0.55) | CTSBCTSLCTSK | |
| SCHEMBL13091685 | 0.89 | CTSK (0.55) | CTSBCTSLCTSK | |
| SCHEMBL463927 | 0.87 | NR1I2 (0.50) | NR1I2CTSBCTSLCTSKABCG2 | |
| SCHEMBL13101551 | 0.84 | CTSK (0.49) | CTSBCTSLCTSK | |
| SCHEMBL16143227 | 0.82 | CMA1 (0.44) | CTSBCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | NR1I2 2511/4885CTSB 39/4885CTSL 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.